Bernstein SocGen Group analyst Courtney Breen reiterated a Market Perform rating and $30.00 price target on Pfizer (NYSE: PFE).

The analyst commented: ": If Novo are successful, this would be a sore loss for Pfizer and would certainly heat up the obesity landscape. However, we believe based on SEC filiings that Novo was unsuccessful in the initial bidding due to anti-trust & regulatory closing concerns (could the deal close). These haven’t gone away. We believe Metsera went for Pfizer’s deal after assessing these risks and given the timing pressure they were under due to the commitment to raise after VESPER1 & -3 data was announced."

For an analyst ratings summary and ratings history on Pfizer click here. For more ratings news on Pfizer click here.

Shares of Pfizer closed at $24.29 yesterday.